Sudden cardiac death in Chagas' heart disease in the contemporary era

Bestetti, Reinaldo B.; Cardinalli-Neto, Augusto

doi:10.1016/j.ijcard.2008.05.024

Cited by 61 publications

(41 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chagas' cardiomyopathy is clinically characterized by the appearance of atrioventricular blocks 4 , dysrhythmias 5 , thromboembolism 6,7 , chest pain 8 , sudden cardiac death 9 and chronic heart failure 10 .…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the six-minute walk test in patients with chronic heart failure associated with Chagas' disease and systemic arterial hypertension

Dourado

Bestetti

Cardinalli-Neto

et al. 2010

Rev. Soc. Bras. Med. Trop.

Self Cite

View full text Add to dashboard Cite

INTRODUCTION: To evaluate physical capacity as determined by the six-minute walk test (6MWT) in patients with chronic heart failure due to Chagas' disease associated with systemic arterial hypertension (Chagas-SAH). METHODS: A total of 98 patients routinely followed at the Cardiomyopathy Outpatient Service were recruited. Of these, 60 (61%) were diagnosed with Chagas disease and 38 (39%) with Chagas-SAH. RESULTS: The distance walked during 6 min was 357.9 ±98 m for Chagas-SAH patients and 395.8 ± 121m for Chagas cardiomyopathy patients (p >0.05). In patients with Chagas-SAH, a negative correlation occurred between the 6MWT and the total score of the Minnesota Living with Heart Failure Questionnaire (r= -0.51; p=0.001). No other correlations were determined between 6MWT values and continuous variables in patients with Chagas-SAH. CONCLUSIONS: The results of the 6MWT in Chagas-SAH patients are similar to those verified in Chagas cardiomyopathy patients with chronic heart failure. Coexistence of SAH does not seem to affect the functional capacity of Chagas cardiomyopathy patients with chronic heart failure.

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluation of the six-minute walk test in patients with chronic heart failure associated with Chagas' disease and systemic arterial hypertension

Dourado

Bestetti

Cardinalli-Neto

et al. 2010

Rev. Soc. Bras. Med. Trop.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Given the presence of a high frequency of patients with bundle branch and fascicular blocks in Chagas' disease with chronic heart failure, as detected in our study, such an increase in digoxin serum concentration could lead to the appearance of life-threatening arrhythmias 18 due to macroreentry and atrioventricular blocks 19 , cardinal manifestations of digoxin toxicity. Nevertheless, the proportion of patients on B-blockers with digoxin serum concentrations ≥ 1ng/ml was similar to that verified in patients on B-blockers with digoxin serum concentrations < 1ng/ml.…”

Section: Discussionmentioning

confidence: 50%

Digoxin serum levels in patients with Chagas' cardiomyopathy and heart failure

Ferrari

Bestetti

Cardinalli-Neto

et al. 2010

Rev. Soc. Bras. Med. Trop.

Self Cite

View full text Add to dashboard Cite

Introduction: The purpose of this study was to determine digoxin serum concentrations in patients with Chagas' cardiomyopathy with chronic heart failure, because little is known concerning this laboratory test in patients with this condition. Methods: This study focuses on 29 (29%) out of 101 patients with chronic heart failure secondary to Chagas' cardiomyopathy receiving digoxin therapy. Digoxin was measured by the immune-enzymatic method. Results: New York Heart Association Functional Class III/IV was noted in 13 (45%) patients. The mean potassium serum level was 4.3± 0.5mEq/L, mean creatinine serum levels 1.4± 0.3dg/100ml, and left ventricular ejection fraction 34.7± 13.8%. The median digoxin serum level was 1.27 (0.55; 1.79)ng/ml. Sixteen (55%) patients had digoxin serum levels higher than 1.0ng/ml. Abnormal digoxin serum levels were verified in 13 (45%) patients. Digoxin serum levels correlated moderately with creatinine serum levels (r = 0.39; p≤ 0.03) and negatively with sodium serum levels (r= -0.38; p= 0.03). Conclusions: Digoxin serum concentration should be measured in patients with Chagas' cardiomyopathy with chronic heart failure receiving digoxin therapy due to the potential for digoxin toxicity.

show abstract

“…Patients should be selected for this type of therapy according to the international guidelines [22] . However, some authors propose that patients with non-sustained ventricular arrhythmia without straight indication for ICD should be referred for programmed ventricular stimulation [23] . Radiofrequency ablation is another option for treating these patients, but sometimes an epicardial approach may be necessary in order to more effectively target the arrhythmia substrate [24] .…”

Section: Discussionmentioning

confidence: 99%

Emerging and under-recognized Chagas cardiomyopathy in non-endemic countries

Cortez

Providência

Ramos

et al. 2012

WJC

View full text Add to dashboard Cite

Due to recent population emigration movements, an epidemic of Chagas disease is currently menacing most developed countries. The authors report the case of a 53-year-old Brazilian woman living in Europe for the last 10 years who developed heart failure symptoms, having a previous symptomatic sinus node disease with a pacemaker implant at age of 40 years. The diagnosis was based on serology and myocardial biopsy and the patient was treated with nifurtimox. The authors emphasize the need of a high level of suspicion in patients with suggestive epidemiology and the need of populational screening of specific high risk groups. New treatment options are also discussed.

show abstract

Sudden cardiac death in Chagas' heart disease in the contemporary era

Cited by 61 publications

References 56 publications

Evaluation of the six-minute walk test in patients with chronic heart failure associated with Chagas' disease and systemic arterial hypertension

Evaluation of the six-minute walk test in patients with chronic heart failure associated with Chagas' disease and systemic arterial hypertension

Digoxin serum levels in patients with Chagas' cardiomyopathy and heart failure

Emerging and under-recognized Chagas cardiomyopathy in non-endemic countries

Contact Info

Product

Resources

About